Drug intelligence / Profile preview

Optimel Manuka+

Development stage
Unknown
Lead developer
Melcare Biomedical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Optimel Manuka+ is a proprietary ophthalmic solution formulated for the management of dry eye symptoms, including sore and irritated eyes and eyelids. The product contains pharmaceutical-grade Leptospermum spp. (Manuka) honey (165 mg/g) as an excipient and glycerin 0.2% as the active ingredient, functioning primarily as a lubricant to relieve dryness and irritation of the eye[4][7][9]. The mechanism of action involves both lubrication from glycerin and antimicrobial/anti-inflammatory effects attributed to medical-grade Manuka honey. The honey component helps reduce bacterial colonization on the eyelid margin, which can contribute to inflammation, poor tear quality, and ocular surface damage in conditions such as tear deficiency or meibomian gland disease[1][5][7]. Clinical studies have shown that application reduces colony-forming units (CFUs) on the eyelids, potentially lowering susceptibility to bacterial conjunctivitis or keratitis while improving dry eye symptoms by reducing bacterial lipase production that disrupts meibomian gland lipids[1][5]. Developed for adjunctive use alongside good eyelid hygiene practices. Adverse effects are generally limited to transient stinging or redness; no serious adverse events have been reported[1][5][7].

Brand names
Optimel Manuka+
Other names
Optimel Manuka+ Dry Eye DropsOptimel Antibacterial Manuka Eye Drops
02

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on Optimel Manuka+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optimel Manuka+.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call